The anti-obesity drug orlistat promotes sensitivity to TRAIL by two different pathways in hormone-refractory prostate cancer cells

Corrigendum in: /10.3892/ijo.2015.3265

  • Authors:
    • Jun Fujiwara
    • Yoshihiro Sowa
    • Mano Horinaka
    • Makoto Koyama
    • Miki Wakada
    • Tsuneharu Miki
    • Toshiyuki Sakai
  • View Affiliations

  • Published online on: February 2, 2012     https://doi.org/10.3892/ijo.2012.1353
  • Pages: 1483-1491
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The administration of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is one of the expected cancer therapeutics. However, improvements are required in therapies against TRAIL-resistant tumor cells. We report, here, that the anti-obesity drug orlistat enhances the sensitivity to TRAIL in hormone-refractory prostate cancer (HRPC) cells through two different pathways. The combination of orlistat and TRAIL remarkably induced apoptosis in TRAIL-resistant HRPC, DU145 and PC3 cells. Orlistat induced the expression of death receptor (DR) 5, which is one of the TRAIL receptors, at both the mRNA and protein levels. The suppression of DR5 with siRNA reduced the apoptosis induced by the combination of orlistat and TRAIL, suggesting that the apoptosis was at least partially due to the upregulation of DR5. Although the upregulation by orlistat of CHOP at both mRNA and protein levels was observed in both cell lines, the activation of the DR5 promoter in DU145 cells was CHOP-dependent, but that in PC3 cells was CHOP-independent. Moreover, orlistat induced reactive oxygen species (ROS), and a ROS scavenger diminished the sensitivity to TRAIL through the suppression of CHOP and DR5 expression in both cell lines. These results suggest that there are two pathways of upregulation of DR5 by orlistat, which are the ROS-CHOP pathway and the ROS-direct pathway. In conclusion, orlistat promotes the sensitivity to TRAIL by ROS-mediated pathways in prostate cancer cells, especially in TRAIL-resistant cells. We believe that the combination of orlistat and TRAIL in HRPC is promising as a new chemotherapeutic strategy.

Related Articles

Journal Cover

May 2012
Volume 40 Issue 5

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Fujiwara, J., Sowa, Y., Horinaka, M., Koyama, M., Wakada, M., Miki, T., & Sakai, T. (2012). The anti-obesity drug orlistat promotes sensitivity to TRAIL by two different pathways in hormone-refractory prostate cancer cells Corrigendum in /10.3892/ijo.2015.3265. International Journal of Oncology, 40, 1483-1491. https://doi.org/10.3892/ijo.2012.1353
MLA
Fujiwara, J., Sowa, Y., Horinaka, M., Koyama, M., Wakada, M., Miki, T., Sakai, T."The anti-obesity drug orlistat promotes sensitivity to TRAIL by two different pathways in hormone-refractory prostate cancer cells Corrigendum in /10.3892/ijo.2015.3265". International Journal of Oncology 40.5 (2012): 1483-1491.
Chicago
Fujiwara, J., Sowa, Y., Horinaka, M., Koyama, M., Wakada, M., Miki, T., Sakai, T."The anti-obesity drug orlistat promotes sensitivity to TRAIL by two different pathways in hormone-refractory prostate cancer cells Corrigendum in /10.3892/ijo.2015.3265". International Journal of Oncology 40, no. 5 (2012): 1483-1491. https://doi.org/10.3892/ijo.2012.1353